title: Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives.
abstract: Radiotherapy is along with surgery and chemotherapy one of the prime treatment modalities in cancer. It is applied in the primary, neoadjuvant as well as the adjuvant setting. Radiation techniques have rapidly evolved during the past decade enabling the delivery of high radiation doses, reducing side-effects in tumour-adjacent normal tissues. While increasing local tumour control, current and future efforts ought to deal with microscopic disease at a distance of the primary tumour, ultimately responsible for disease-progression. This review explores the possibility of bimodal treatment combining radiotherapy with immunotherapy.
authors.affiliation: Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands. Electronic address: nicolle.rekers@maastrichtuniversity.nl.
authors.forename: N H
authors.initials: NH
authors.lastname: Rekers
authors.affiliation: Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.
authors.forename: E G C
authors.initials: EG
authors.lastname: Troost
authors.affiliation: Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.
authors.forename: C M L
authors.initials: CM
authors.lastname: Zegers
authors.affiliation: Department of internal medicine, GROW - School for oncology and developmental biology, Maastricht university medical centre, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.
authors.forename: W T V
authors.initials: WT
authors.lastname: Germeraad
authors.affiliation: Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.
authors.forename: L J
authors.initials: LJ
authors.lastname: Dubois
authors.affiliation: Department of radiation oncology (MaastRO Lab), GROW - School for oncology and developmental biology, Maastricht university medical center, UNS 50/23, PO Box 616, 6200 MD Maastricht, The Netherlands.
authors.forename: P
authors.initials: P
authors.lastname: Lambin
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use; D024201:Bystander Effect; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors; D016923:Cell Death / Q000276:immunology / Q000528:radiation effects; D003131:Combined Modality Therapy; D019583:Dose Fractionation, Radiation; D005544:Forecasting; D006801:Humans; D007157:Immunologic Surveillance / Q000528:radiation effects*; D007167:Immunotherapy; D000074324:Ipilimumab; D051379:Mice; D058990:Molecular Targeted Therapy; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D009369:Neoplasms / Q000276:immunology / Q000601:surgery* / Q000628:therapy; D009374:Neoplasms, Experimental / Q000601:surgery / Q000628:therapy; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors; D016634:Radiosurgery; D016032:Randomized Controlled Trials as Topic; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D019139:Tumor Escape / Q000276:immunology / Q000528:radiation effects; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9 / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D000074324:Ipilimumab; D009363:Neoplasm Proteins; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; D053261:Tumor Necrosis Factor Receptor Superfamily, Member 9
keywords: Immunotherapy; Immunothérapie; Radiothérapie stéréotaxique ablative; Stereotactic ablative body radiotherapy